GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (FRA:6MX) » Definitions » Total Long-Term Liabilities

Eidos Therapeutics (FRA:6MX) Total Long-Term Liabilities : €20.94 Mil (As of Sep. 2020)


View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Eidos Therapeutics's Total Long-Term Liabilities for the quarter that ended in Sep. 2020 was €20.94 Mil.

Eidos Therapeutics Total Long-Term Liabilities Historical Data

The historical data trend for Eidos Therapeutics's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics Total Long-Term Liabilities Chart

Eidos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Total Long-Term Liabilities
3.94 14.62 0.28 19.77

Eidos Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.42 19.77 19.84 19.51 20.94

Eidos Therapeutics Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Eidos Therapeutics Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Eidos Therapeutics (FRA:6MX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (FRA:6MX) » Definitions » Total Long-Term Liabilities
Comparable Companies
CORT ZYME ARVN XNCR LGND IMVT MDGL TBPH SWTX ZGNX OCSE:NOVO B ASX:CSL VRTX REGN XKRX:207940 SGEN MRNA ALXN XKRX:068270 INCY
Traded in Other Exchanges
N/A
Address
101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104
Website
https://www.eidostx.com
Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.

Eidos Therapeutics (FRA:6MX) Headlines

No Headlines